Document is current
Any future updates will be listed below
-
Authors
Fang, Jingwen
Luo, Songwen
Li, Shouzhen
Xu, Yehong
Wang, Jing
Shan, Benjie
Hu, Mingjun
Yu, Qiaoni
Zhang, Wen
Liu, Ke
Shao, Yunying
Yang, Jiaxuan
Zhou, YouYang
Xu, Guangtao
Yao, Xinfeng
Sun, Ruoming
Zhang, Mengyuan
Li, Kun
Xu, Xihai
Zhang, Yongliang
Zhang, Zhihong
Han, Xinghua
Pan, Yueyin
Guo, Chuang
Qu, Kun
-
Funding
Funding for this research was provided by:
USTC Research Funds of the Double First-Class Initiative (YD9990006004)
USTC Research Funds of the Double First-Class Initiative (YD9100002032)
Anhui Province Natural Science Foundation (2508085QC071)
National Natural Science Foundation of China (32270978)
National Natural Science Foundation of China (T2125012)
Fundamental Research Funds for the Central Universities (WK9100000086)
the National Key R&D Program of China (2022YFA1303200)
the Strategic Priority Research Program of Chinese Academy of Sciences (XDB0940301)
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 24 December 2025
First Online: 6 January 2026
Declarations
:
: This study was approved by the ethics committee of The First Affiliated Hospital of the University of Science and Technology of China (No. 2022-KY-264). All participants provided written informed consent to participate in this study. All procedures involving human participants conformed to the principles of the Helsinki Declaration. The animal model study scheme was approved by the Institutional Animal Care and Use Committee (IACUC) of Precedo Pharmaceuticals Co., Ltd. (Approval No. IACUC-20220801). During the study, animal breeding and use were strictly conducted in accordance with the regulations and guidelines of the International Management Committee for Assessment and Certification of Laboratory Animals.
: Not applicable.
: Jingwen Fang is the chief executive officer of HanGene Biotech. Kun Qu and Chuang Guo are science advisers of HanGene Biotech. Authors Yunying Shao, Jiaxuan Yang, YouYang Zhou are employees of HanGene Biotech. The remaining authors declare that they have no competing interests.
